Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6O5N

Tubulin-RB3_SLD-TTL in complex with compound 10ab

Summary for 6O5N
Entry DOI10.2210/pdb6o5n/pdb
Related6O5M
DescriptorTubulin alpha-1B chain, [2-(4-methyl-1H-indol-3-yl)-1H-imidazol-5-yl](3,4,5-trimethoxyphenyl)methanone, Tubulin beta-2B chain, ... (11 entities in total)
Functional Keywordsmicrotubule inhibitor, colchicine, cancer, cell cycle
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains6
Total formula weight264564.13
Authors
Kumar, G.,Wang, Y.,Li, W.,White, S.W. (deposition date: 2019-03-04, release date: 2019-07-10, Last modification date: 2024-03-13)
Primary citationWang, Q.,Arnst, K.E.,Wang, Y.,Kumar, G.,Ma, D.,White, S.W.,Miller, D.D.,Li, W.,Li, W.
Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin.
J.Med.Chem., 62:6734-6750, 2019
Cited by
PubMed Abstract: ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure-activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogues, most notably and . The crystal structures of and in complex with tubulin confirmed their improved molecular interactions to the colchicine site. In vitro, biological studies showed that new ABI-231 analogues disrupt tubulin polymerization, promote microtubule fragmentation, and inhibit cancer cell migration. In vivo, analogue not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model. In addition, pharmacological screening suggested that has a low risk of potential off-target function.
PubMed: 31251599
DOI: 10.1021/acs.jmedchem.9b00706
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.003 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon